441 related articles for article (PubMed ID: 18445842)
21. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Agarwala SS; Ferri W; Gooding W; Kirkwood JM
Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
[TBL] [Abstract][Full Text] [Related]
22. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
23. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
24. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R
J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509
[TBL] [Abstract][Full Text] [Related]
29. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
32. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
33. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
34. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
35. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
36. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Paz-Ares LG; Biesma B; Heigener D; von Pawel J; Eisen T; Bennouna J; Zhang L; Liao M; Sun Y; Gans S; Syrigos K; Le Marie E; Gottfried M; Vansteenkiste J; Alberola V; Strauss UP; Montegriffo E; Ong TJ; Santoro A;
J Clin Oncol; 2012 Sep; 30(25):3084-92. PubMed ID: 22851564
[TBL] [Abstract][Full Text] [Related]
37. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]